 | • レポートコード：MRC2-11QY06842 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は多形性膠芽腫治療薬のグローバル市場について調査・分析したレポートです。種類別（テモゾロミド、ベバコズマブ、カルムスチン）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別多形性膠芽腫治療薬の競争状況、市場シェア ・世界の多形性膠芽腫治療薬市場：種類別市場規模 2015年-2020年（テモゾロミド、ベバコズマブ、カルムスチン） ・世界の多形性膠芽腫治療薬市場：種類別市場規模予測 2021年-2026年（テモゾロミド、ベバコズマブ、カルムスチン） ・世界の多形性膠芽腫治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の多形性膠芽腫治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の多形性膠芽腫治療薬市場分析：米国、カナダ ・ヨーロッパの多形性膠芽腫治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの多形性膠芽腫治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の多形性膠芽腫治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの多形性膠芽腫治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Arbor Pharmaceuticals、Bristol-Myers Squibb、Eisai、F. Hoffmann-La Roche、Merck ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or the neuron. The one which develops in the glial cells (astrocytes and oligodendrocytes) is called glioma, the commonest forms of brain tumor.
Currently unavailable therapies and prognosis for the treatment of GBM is expected to impact the market growth positively through to 2022. Presence of the treatment options which do not increase the overall survival rate in patients such as surgical resection, which is followed by chemotherapy and radiotherapy, is another factor attributing towards the expected growth of this market. Moreover, the fact that glioma stem cells resist conventional treatments also raises urgent need for alternative treatment therapies for glioblastoma multiforme thus driving the market. Increasing R&D in gene therapy and molecular biotechnology for the treatment of CNS associated disorders and cancer is anticipated to fuel the market growth over the forecast period. However, high expenditure involved in research employing genomics based research is a key restraint for market.
Market Analysis and Insights: Global Glioblastoma Multiforme Therapeutics Market
The global Glioblastoma Multiforme Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Glioblastoma Multiforme Therapeutics Scope and Market Size
Glioblastoma Multiforme Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Glioblastoma Multiforme Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Glioblastoma Multiforme Therapeutics market is segmented into
Temozolomide
Bevacozumab
Carmustine
Segment by Application, the Glioblastoma Multiforme Therapeutics market is segmented into
Hospitals
Clinics
Others
Regional and Country-level Analysis
The Glioblastoma Multiforme Therapeutics market is analysed and market size information is provided by regions (countries).
The key regions covered in the Glioblastoma Multiforme Therapeutics market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Glioblastoma Multiforme Therapeutics Market Share Analysis
Glioblastoma Multiforme Therapeutics market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Glioblastoma Multiforme Therapeutics business, the date to enter into the Glioblastoma Multiforme Therapeutics market, Glioblastoma Multiforme Therapeutics product introduction, recent developments, etc.
The major vendors covered:
Arbor Pharmaceuticals
Bristol-Myers Squibb
Eisai
F. Hoffmann-La Roche
Merck
…
1 Study Coverage
1.1 Glioblastoma Multiforme Therapeutics Product Introduction
1.2 Market Segments
1.3 Key Glioblastoma Multiforme Therapeutics Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Glioblastoma Multiforme Therapeutics Market Size Growth Rate by Type
1.4.2 Temozolomide
1.4.3 Bevacozumab
1.4.4 Carmustine
1.5 Market by Application
1.5.1 Global Glioblastoma Multiforme Therapeutics Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Glioblastoma Multiforme Therapeutics Market Size, Estimates and Forecasts
2.1.1 Global Glioblastoma Multiforme Therapeutics Revenue 2015-2026
2.1.2 Global Glioblastoma Multiforme Therapeutics Sales 2015-2026
2.2 Global Glioblastoma Multiforme Therapeutics, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Glioblastoma Multiforme Therapeutics Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Glioblastoma Multiforme Therapeutics Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Glioblastoma Multiforme Therapeutics Competitor Landscape by Players
3.1 Glioblastoma Multiforme Therapeutics Sales by Manufacturers
3.1.1 Glioblastoma Multiforme Therapeutics Sales by Manufacturers (2015-2020)
3.1.2 Glioblastoma Multiforme Therapeutics Sales Market Share by Manufacturers (2015-2020)
3.2 Glioblastoma Multiforme Therapeutics Revenue by Manufacturers
3.2.1 Glioblastoma Multiforme Therapeutics Revenue by Manufacturers (2015-2020)
3.2.2 Glioblastoma Multiforme Therapeutics Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Glioblastoma Multiforme Therapeutics Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Glioblastoma Multiforme Therapeutics Revenue in 2019
3.2.5 Global Glioblastoma Multiforme Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Glioblastoma Multiforme Therapeutics Price by Manufacturers
3.4 Glioblastoma Multiforme Therapeutics Manufacturing Base Distribution, Product Types
3.4.1 Glioblastoma Multiforme Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Glioblastoma Multiforme Therapeutics Product Type
3.4.3 Date of International Manufacturers Enter into Glioblastoma Multiforme Therapeutics Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Glioblastoma Multiforme Therapeutics Market Size by Type (2015-2020)
4.1.1 Global Glioblastoma Multiforme Therapeutics Sales by Type (2015-2020)
4.1.2 Global Glioblastoma Multiforme Therapeutics Revenue by Type (2015-2020)
4.1.3 Glioblastoma Multiforme Therapeutics Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Glioblastoma Multiforme Therapeutics Market Size Forecast by Type (2021-2026)
4.2.1 Global Glioblastoma Multiforme Therapeutics Sales Forecast by Type (2021-2026)
4.2.2 Global Glioblastoma Multiforme Therapeutics Revenue Forecast by Type (2021-2026)
4.2.3 Glioblastoma Multiforme Therapeutics Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Glioblastoma Multiforme Therapeutics Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Glioblastoma Multiforme Therapeutics Market Size by Application (2015-2020)
5.1.1 Global Glioblastoma Multiforme Therapeutics Sales by Application (2015-2020)
5.1.2 Global Glioblastoma Multiforme Therapeutics Revenue by Application (2015-2020)
5.1.3 Glioblastoma Multiforme Therapeutics Price by Application (2015-2020)
5.2 Glioblastoma Multiforme Therapeutics Market Size Forecast by Application (2021-2026)
5.2.1 Global Glioblastoma Multiforme Therapeutics Sales Forecast by Application (2021-2026)
5.2.2 Global Glioblastoma Multiforme Therapeutics Revenue Forecast by Application (2021-2026)
5.2.3 Global Glioblastoma Multiforme Therapeutics Price Forecast by Application (2021-2026)
6 North America
6.1 North America Glioblastoma Multiforme Therapeutics by Country
6.1.1 North America Glioblastoma Multiforme Therapeutics Sales by Country
6.1.2 North America Glioblastoma Multiforme Therapeutics Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Glioblastoma Multiforme Therapeutics Market Facts & Figures by Type
6.3 North America Glioblastoma Multiforme Therapeutics Market Facts & Figures by Application
7 Europe
7.1 Europe Glioblastoma Multiforme Therapeutics by Country
7.1.1 Europe Glioblastoma Multiforme Therapeutics Sales by Country
7.1.2 Europe Glioblastoma Multiforme Therapeutics Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Glioblastoma Multiforme Therapeutics Market Facts & Figures by Type
7.3 Europe Glioblastoma Multiforme Therapeutics Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Glioblastoma Multiforme Therapeutics by Region
8.1.1 Asia Pacific Glioblastoma Multiforme Therapeutics Sales by Region
8.1.2 Asia Pacific Glioblastoma Multiforme Therapeutics Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Glioblastoma Multiforme Therapeutics Market Facts & Figures by Type
8.3 Asia Pacific Glioblastoma Multiforme Therapeutics Market Facts & Figures by Application
9 Latin America
9.1 Latin America Glioblastoma Multiforme Therapeutics by Country
9.1.1 Latin America Glioblastoma Multiforme Therapeutics Sales by Country
9.1.2 Latin America Glioblastoma Multiforme Therapeutics Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Glioblastoma Multiforme Therapeutics Market Facts & Figures by Type
9.3 Central & South America Glioblastoma Multiforme Therapeutics Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Glioblastoma Multiforme Therapeutics by Country
10.1.1 Middle East and Africa Glioblastoma Multiforme Therapeutics Sales by Country
10.1.2 Middle East and Africa Glioblastoma Multiforme Therapeutics Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Glioblastoma Multiforme Therapeutics Market Facts & Figures by Type
10.3 Middle East and Africa Glioblastoma Multiforme Therapeutics Market Facts & Figures by Application
11 Company Profiles
11.1 Arbor Pharmaceuticals
11.1.1 Arbor Pharmaceuticals Corporation Information
11.1.2 Arbor Pharmaceuticals Description and Business Overview
11.1.3 Arbor Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Arbor Pharmaceuticals Glioblastoma Multiforme Therapeutics Products Offered
11.1.5 Arbor Pharmaceuticals Related Developments
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Corporation Information
11.2.2 Bristol-Myers Squibb Description and Business Overview
11.2.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Bristol-Myers Squibb Glioblastoma Multiforme Therapeutics Products Offered
11.2.5 Bristol-Myers Squibb Related Developments
11.3 Eisai
11.3.1 Eisai Corporation Information
11.3.2 Eisai Description and Business Overview
11.3.3 Eisai Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Eisai Glioblastoma Multiforme Therapeutics Products Offered
11.3.5 Eisai Related Developments
11.4 F. Hoffmann-La Roche
11.4.1 F. Hoffmann-La Roche Corporation Information
11.4.2 F. Hoffmann-La Roche Description and Business Overview
11.4.3 F. Hoffmann-La Roche Sales, Revenue and Gross Margin (2015-2020)
11.4.4 F. Hoffmann-La Roche Glioblastoma Multiforme Therapeutics Products Offered
11.4.5 F. Hoffmann-La Roche Related Developments
11.5 Merck
11.5.1 Merck Corporation Information
11.5.2 Merck Description and Business Overview
11.5.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Merck Glioblastoma Multiforme Therapeutics Products Offered
11.5.5 Merck Related Developments
11.1 Arbor Pharmaceuticals
11.1.1 Arbor Pharmaceuticals Corporation Information
11.1.2 Arbor Pharmaceuticals Description and Business Overview
11.1.3 Arbor Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Arbor Pharmaceuticals Glioblastoma Multiforme Therapeutics Products Offered
11.1.5 Arbor Pharmaceuticals Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Glioblastoma Multiforme Therapeutics Market Estimates and Projections by Region
12.1.1 Global Glioblastoma Multiforme Therapeutics Sales Forecast by Regions 2021-2026
12.1.2 Global Glioblastoma Multiforme Therapeutics Revenue Forecast by Regions 2021-2026
12.2 North America Glioblastoma Multiforme Therapeutics Market Size Forecast (2021-2026)
12.2.1 North America: Glioblastoma Multiforme Therapeutics Sales Forecast (2021-2026)
12.2.2 North America: Glioblastoma Multiforme Therapeutics Revenue Forecast (2021-2026)
12.2.3 North America: Glioblastoma Multiforme Therapeutics Market Size Forecast by Country (2021-2026)
12.3 Europe Glioblastoma Multiforme Therapeutics Market Size Forecast (2021-2026)
12.3.1 Europe: Glioblastoma Multiforme Therapeutics Sales Forecast (2021-2026)
12.3.2 Europe: Glioblastoma Multiforme Therapeutics Revenue Forecast (2021-2026)
12.3.3 Europe: Glioblastoma Multiforme Therapeutics Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Glioblastoma Multiforme Therapeutics Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Glioblastoma Multiforme Therapeutics Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Glioblastoma Multiforme Therapeutics Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Glioblastoma Multiforme Therapeutics Market Size Forecast by Region (2021-2026)
12.5 Latin America Glioblastoma Multiforme Therapeutics Market Size Forecast (2021-2026)
12.5.1 Latin America: Glioblastoma Multiforme Therapeutics Sales Forecast (2021-2026)
12.5.2 Latin America: Glioblastoma Multiforme Therapeutics Revenue Forecast (2021-2026)
12.5.3 Latin America: Glioblastoma Multiforme Therapeutics Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Glioblastoma Multiforme Therapeutics Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Glioblastoma Multiforme Therapeutics Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Glioblastoma Multiforme Therapeutics Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Glioblastoma Multiforme Therapeutics Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Glioblastoma Multiforme Therapeutics Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Glioblastoma Multiforme Therapeutics Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Glioblastoma Multiforme Therapeutics Market Segments
Table 2. Ranking of Global Top Glioblastoma Multiforme Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Glioblastoma Multiforme Therapeutics Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Temozolomide
Table 5. Major Manufacturers of Bevacozumab
Table 6. Major Manufacturers of Carmustine
Table 7. Global Glioblastoma Multiforme Therapeutics Market Size Growth Rate by Application 2020-2026 (K MT)
Table 8. Global Glioblastoma Multiforme Therapeutics Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 9. Global Glioblastoma Multiforme Therapeutics Sales by Regions 2015-2020 (K MT)
Table 10. Global Glioblastoma Multiforme Therapeutics Sales Market Share by Regions (2015-2020)
Table 11. Global Glioblastoma Multiforme Therapeutics Revenue by Regions 2015-2020 (US$ Million)
Table 12. Global Glioblastoma Multiforme Therapeutics Sales by Manufacturers (2015-2020) (K MT)
Table 13. Global Glioblastoma Multiforme Therapeutics Sales Share by Manufacturers (2015-2020)
Table 14. Global Glioblastoma Multiforme Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 15. Global Glioblastoma Multiforme Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Glioblastoma Multiforme Therapeutics as of 2019)
Table 16. Glioblastoma Multiforme Therapeutics Revenue by Manufacturers (2015-2020) (US$ Million)
Table 17. Glioblastoma Multiforme Therapeutics Revenue Share by Manufacturers (2015-2020)
Table 18. Key Manufacturers Glioblastoma Multiforme Therapeutics Price (2015-2020) (USD/MT)
Table 19. Glioblastoma Multiforme Therapeutics Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers Glioblastoma Multiforme Therapeutics Product Type
Table 21. Date of International Manufacturers Enter into Glioblastoma Multiforme Therapeutics Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Global Glioblastoma Multiforme Therapeutics Sales by Type (2015-2020) (K MT)
Table 24. Global Glioblastoma Multiforme Therapeutics Sales Share by Type (2015-2020)
Table 25. Global Glioblastoma Multiforme Therapeutics Revenue by Type (2015-2020) (US$ Million)
Table 26. Global Glioblastoma Multiforme Therapeutics Revenue Share by Type (2015-2020)
Table 27. Glioblastoma Multiforme Therapeutics Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 28. Global Glioblastoma Multiforme Therapeutics Sales by Application (2015-2020) (K MT)
Table 29. Global Glioblastoma Multiforme Therapeutics Sales Share by Application (2015-2020)
Table 30. North America Glioblastoma Multiforme Therapeutics Sales by Country (2015-2020) (K MT)
Table 31. North America Glioblastoma Multiforme Therapeutics Sales Market Share by Country (2015-2020)
Table 32. North America Glioblastoma Multiforme Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 33. North America Glioblastoma Multiforme Therapeutics Revenue Market Share by Country (2015-2020)
Table 34. North America Glioblastoma Multiforme Therapeutics Sales by Type (2015-2020) (K MT)
Table 35. North America Glioblastoma Multiforme Therapeutics Sales Market Share by Type (2015-2020)
Table 36. North America Glioblastoma Multiforme Therapeutics Sales by Application (2015-2020) (K MT)
Table 37. North America Glioblastoma Multiforme Therapeutics Sales Market Share by Application (2015-2020)
Table 38. Europe Glioblastoma Multiforme Therapeutics Sales by Country (2015-2020) (K MT)
Table 39. Europe Glioblastoma Multiforme Therapeutics Sales Market Share by Country (2015-2020)
Table 40. Europe Glioblastoma Multiforme Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 41. Europe Glioblastoma Multiforme Therapeutics Revenue Market Share by Country (2015-2020)
Table 42. Europe Glioblastoma Multiforme Therapeutics Sales by Type (2015-2020) (K MT)
Table 43. Europe Glioblastoma Multiforme Therapeutics Sales Market Share by Type (2015-2020)
Table 44. Europe Glioblastoma Multiforme Therapeutics Sales by Application (2015-2020) (K MT)
Table 45. Europe Glioblastoma Multiforme Therapeutics Sales Market Share by Application (2015-2020)
Table 46. Asia Pacific Glioblastoma Multiforme Therapeutics Sales by Region (2015-2020) (K MT)
Table 47. Asia Pacific Glioblastoma Multiforme Therapeutics Sales Market Share by Region (2015-2020)
Table 48. Asia Pacific Glioblastoma Multiforme Therapeutics Revenue by Region (2015-2020) (US$ Million)
Table 49. Asia Pacific Glioblastoma Multiforme Therapeutics Revenue Market Share by Region (2015-2020)
Table 50. Asia Pacific Glioblastoma Multiforme Therapeutics Sales by Type (2015-2020) (K MT)
Table 51. Asia Pacific Glioblastoma Multiforme Therapeutics Sales Market Share by Type (2015-2020)
Table 52. Asia Pacific Glioblastoma Multiforme Therapeutics Sales by Application (2015-2020) (K MT)
Table 53. Asia Pacific Glioblastoma Multiforme Therapeutics Sales Market Share by Application (2015-2020)
Table 54. Latin America Glioblastoma Multiforme Therapeutics Sales by Country (2015-2020) (K MT)
Table 55. Latin America Glioblastoma Multiforme Therapeutics Sales Market Share by Country (2015-2020)
Table 56. Latin Americaa Glioblastoma Multiforme Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 57. Latin America Glioblastoma Multiforme Therapeutics Revenue Market Share by Country (2015-2020)
Table 58. Latin America Glioblastoma Multiforme Therapeutics Sales by Type (2015-2020) (K MT)
Table 59. Latin America Glioblastoma Multiforme Therapeutics Sales Market Share by Type (2015-2020)
Table 60. Latin America Glioblastoma Multiforme Therapeutics Sales by Application (2015-2020) (K MT)
Table 61. Latin America Glioblastoma Multiforme Therapeutics Sales Market Share by Application (2015-2020)
Table 62. Middle East and Africa Glioblastoma Multiforme Therapeutics Sales by Country (2015-2020) (K MT)
Table 63. Middle East and Africa Glioblastoma Multiforme Therapeutics Sales Market Share by Country (2015-2020)
Table 64. Middle East and Africa Glioblastoma Multiforme Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 65. Middle East and Africa Glioblastoma Multiforme Therapeutics Revenue Market Share by Country (2015-2020)
Table 66. Middle East and Africa Glioblastoma Multiforme Therapeutics Sales by Type (2015-2020) (K MT)
Table 67. Middle East and Africa Glioblastoma Multiforme Therapeutics Sales Market Share by Type (2015-2020)
Table 68. Middle East and Africa Glioblastoma Multiforme Therapeutics Sales by Application (2015-2020) (K MT)
Table 69. Middle East and Africa Glioblastoma Multiforme Therapeutics Sales Market Share by Application (2015-2020)
Table 70. Arbor Pharmaceuticals Corporation Information
Table 71. Arbor Pharmaceuticals Description and Major Businesses
Table 72. Arbor Pharmaceuticals Glioblastoma Multiforme Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 73. Arbor Pharmaceuticals Product
Table 74. Arbor Pharmaceuticals Recent Development
Table 75. Bristol-Myers Squibb Corporation Information
Table 76. Bristol-Myers Squibb Description and Major Businesses
Table 77. Bristol-Myers Squibb Glioblastoma Multiforme Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 78. Bristol-Myers Squibb Product
Table 79. Bristol-Myers Squibb Recent Development
Table 80. Eisai Corporation Information
Table 81. Eisai Description and Major Businesses
Table 82. Eisai Glioblastoma Multiforme Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 83. Eisai Product
Table 84. Eisai Recent Development
Table 85. F. Hoffmann-La Roche Corporation Information
Table 86. F. Hoffmann-La Roche Description and Major Businesses
Table 87. F. Hoffmann-La Roche Glioblastoma Multiforme Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 88. F. Hoffmann-La Roche Product
Table 89. F. Hoffmann-La Roche Recent Development
Table 90. Merck Corporation Information
Table 91. Merck Description and Major Businesses
Table 92. Merck Glioblastoma Multiforme Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 93. Merck Product
Table 94. Merck Recent Development
Table 95. Global Glioblastoma Multiforme Therapeutics Sales Forecast by Regions (2021-2026) (K MT)
Table 96. Global Glioblastoma Multiforme Therapeutics Sales Market Share Forecast by Regions (2021-2026)
Table 97. Global Glioblastoma Multiforme Therapeutics Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 98. Global Glioblastoma Multiforme Therapeutics Revenue Market Share Forecast by Regions (2021-2026)
Table 99. North America: Glioblastoma Multiforme Therapeutics Sales Forecast by Country (2021-2026) (K MT)
Table 100. North America: Glioblastoma Multiforme Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 101. Europe: Glioblastoma Multiforme Therapeutics Sales Forecast by Country (2021-2026) (K MT)
Table 102. Europe: Glioblastoma Multiforme Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 103. Asia Pacific: Glioblastoma Multiforme Therapeutics Sales Forecast by Region (2021-2026) (K MT)
Table 104. Asia Pacific: Glioblastoma Multiforme Therapeutics Revenue Forecast by Region (2021-2026) (US$ Million)
Table 105. Latin America: Glioblastoma Multiforme Therapeutics Sales Forecast by Country (2021-2026) (K MT)
Table 106. Latin America: Glioblastoma Multiforme Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 107. Middle East and Africa: Glioblastoma Multiforme Therapeutics Sales Forecast by Country (2021-2026) (K MT)
Table 108. Middle East and Africa: Glioblastoma Multiforme Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 109. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 110. Key Challenges
Table 111. Market Risks
Table 112. Main Points Interviewed from Key Glioblastoma Multiforme Therapeutics Players
Table 113. Glioblastoma Multiforme Therapeutics Customers List
Table 114. Glioblastoma Multiforme Therapeutics Distributors List
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Glioblastoma Multiforme Therapeutics Product Picture
Figure 2. Global Glioblastoma Multiforme Therapeutics Sales Market Share by Type in 2020 & 2026
Figure 3. Temozolomide Product Picture
Figure 4. Bevacozumab Product Picture
Figure 5. Carmustine Product Picture
Figure 6. Global Glioblastoma Multiforme Therapeutics Sales Market Share by Application in 2020 & 2026
Figure 7. Hospitals
Figure 8. Clinics
Figure 9. Others
Figure 10. Glioblastoma Multiforme Therapeutics Report Years Considered
Figure 11. Global Glioblastoma Multiforme Therapeutics Market Size 2015-2026 (US$ Million)
Figure 12. Global Glioblastoma Multiforme Therapeutics Sales 2015-2026 (K MT)
Figure 13. Global Glioblastoma Multiforme Therapeutics Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Glioblastoma Multiforme Therapeutics Sales Market Share by Region (2015-2020)
Figure 15. Global Glioblastoma Multiforme Therapeutics Sales Market Share by Region in 2019
Figure 16. Global Glioblastoma Multiforme Therapeutics Revenue Market Share by Region (2015-2020)
Figure 17. Global Glioblastoma Multiforme Therapeutics Revenue Market Share by Region in 2019
Figure 18. Global Glioblastoma Multiforme Therapeutics Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Glioblastoma Multiforme Therapeutics Revenue in 2019
Figure 20. Glioblastoma Multiforme Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Glioblastoma Multiforme Therapeutics Sales Market Share by Type (2015-2020)
Figure 22. Global Glioblastoma Multiforme Therapeutics Sales Market Share by Type in 2019
Figure 23. Global Glioblastoma Multiforme Therapeutics Revenue Market Share by Type (2015-2020)
Figure 24. Global Glioblastoma Multiforme Therapeutics Revenue Market Share by Type in 2019
Figure 25. Global Glioblastoma Multiforme Therapeutics Market Share by Price Range (2015-2020)
Figure 26. Global Glioblastoma Multiforme Therapeutics Sales Market Share by Application (2015-2020)
Figure 27. Global Glioblastoma Multiforme Therapeutics Sales Market Share by Application in 2019
Figure 28. Global Glioblastoma Multiforme Therapeutics Revenue Market Share by Application (2015-2020)
Figure 29. Global Glioblastoma Multiforme Therapeutics Revenue Market Share by Application in 2019
Figure 30. North America Glioblastoma Multiforme Therapeutics Sales Growth Rate 2015-2020 (K MT)
Figure 31. North America Glioblastoma Multiforme Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Glioblastoma Multiforme Therapeutics Sales Market Share by Country in 2019
Figure 33. North America Glioblastoma Multiforme Therapeutics Revenue Market Share by Country in 2019
Figure 34. U.S. Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 35. U.S. Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 37. Canada Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Glioblastoma Multiforme Therapeutics Market Share by Type in 2019
Figure 39. North America Glioblastoma Multiforme Therapeutics Market Share by Application in 2019
Figure 40. Europe Glioblastoma Multiforme Therapeutics Sales Growth Rate 2015-2020 (K MT)
Figure 41. Europe Glioblastoma Multiforme Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Glioblastoma Multiforme Therapeutics Sales Market Share by Country in 2019
Figure 43. Europe Glioblastoma Multiforme Therapeutics Revenue Market Share by Country in 2019
Figure 44. Germany Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 45. Germany Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 47. France Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 49. U.K. Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 51. Italy Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 53. Russia Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Glioblastoma Multiforme Therapeutics Market Share by Type in 2019
Figure 55. Europe Glioblastoma Multiforme Therapeutics Market Share by Application in 2019
Figure 56. Asia Pacific Glioblastoma Multiforme Therapeutics Sales Growth Rate 2015-2020 (K MT)
Figure 57. Asia Pacific Glioblastoma Multiforme Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Glioblastoma Multiforme Therapeutics Sales Market Share by Region in 2019
Figure 59. Asia Pacific Glioblastoma Multiforme Therapeutics Revenue Market Share by Region in 2019
Figure 60. China Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 61. China Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 63. Japan Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 65. South Korea Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 67. India Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 69. Australia Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 71. Taiwan Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 73. Indonesia Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 75. Thailand Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 77. Malaysia Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 79. Philippines Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 81. Vietnam Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Glioblastoma Multiforme Therapeutics Market Share by Type in 2019
Figure 83. Asia Pacific Glioblastoma Multiforme Therapeutics Market Share by Application in 2019
Figure 84. Latin America Glioblastoma Multiforme Therapeutics Sales Growth Rate 2015-2020 (K MT)
Figure 85. Latin America Glioblastoma Multiforme Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Glioblastoma Multiforme Therapeutics Sales Market Share by Country in 2019
Figure 87. Latin America Glioblastoma Multiforme Therapeutics Revenue Market Share by Country in 2019
Figure 88. Mexico Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 89. Mexico Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 91. Brazil Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 93. Argentina Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Glioblastoma Multiforme Therapeutics Market Share by Type in 2019
Figure 95. Latin America Glioblastoma Multiforme Therapeutics Market Share by Application in 2019
Figure 96. Middle East and Africa Glioblastoma Multiforme Therapeutics Sales Growth Rate 2015-2020 (K MT)
Figure 97. Middle East and Africa Glioblastoma Multiforme Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Glioblastoma Multiforme Therapeutics Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Glioblastoma Multiforme Therapeutics Revenue Market Share by Country in 2019
Figure 100. Turkey Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 101. Turkey Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 103. Saudi Arabia Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. U.A.E Glioblastoma Multiforme Therapeutics Sales Growth Rate (2015-2020) (K MT)
Figure 105. U.A.E Glioblastoma Multiforme Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Glioblastoma Multiforme Therapeutics Market Share by Type in 2019
Figure 107. Middle East and Africa Glioblastoma Multiforme Therapeutics Market Share by Application in 2019
Figure 108. North America Glioblastoma Multiforme Therapeutics Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 109. North America Glioblastoma Multiforme Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 110. Europe Glioblastoma Multiforme Therapeutics Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 111. Europe Glioblastoma Multiforme Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Asia Pacific Glioblastoma Multiforme Therapeutics Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 113. Asia Pacific Glioblastoma Multiforme Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Latin America Glioblastoma Multiforme Therapeutics Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 115. Latin America Glioblastoma Multiforme Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Middle East and Africa Glioblastoma Multiforme Therapeutics Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 117. Middle East and Africa Glioblastoma Multiforme Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Porter's Five Forces Analysis
Figure 119. Channels of Distribution
Figure 120. Distributors Profiles
Figure 121. Bottom-up and Top-down Approaches for This Report
Figure 122. Data Triangulation
Figure 123. Key Executives Interviewed
多形性膠芽腫（GBM）治療薬の世界市場（～2026年） Glioblastoma multiforme (GBM) is among the most difficult of tumors to treat, and despite all efforts, median overall survival remains at approximately 12 months. Malignant gliomas are included in the category of rare diseases, and the orphan drug status is granted for the drug candidates in the pip…- 多形性膠芽腫（GBM）治療の世界市場（～2026年） Glioblastoma is a fast-growing, aggressive type of central nervous system tumor that forms on the supportive tissue of the brain. Global glioblastoma multiforme treatment market is expected to witness significant growth over the forecast period owing to the rising incidence of oncology diseases and …
- 多形性膠芽腫（GBM）再発治療の世界市場（～2026年） Recurrent glioblastoma multiforme is the most aggressive cancer that begins within the brain. The increasing incidence of seizure is expected to drive the recurrent glioblastoma multiforme treatment market. Market Analysis and Insights: Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market…
- メラノサイトタンパク質PMELの世界市場（～2026年） Market Analysis and Insights: Global Melanocyte Protein PMEL Market The global Melanocyte Protein PMEL market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Melanocyte Protein PMEL Scope and Market Size Melanocyte Protein PM…
- 血友病A・B治療材料の世界市場（～2026年） Hemophilia is a rare, inherited disorder in which blood doesn’t clot normally due to the lack of sufficient blood clotting factor. Clotting factor is a protein required for blood clotting to occur normally. Novel treatments for people suffering from hemophilia and other different bleeding problems h…